Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Ipamorelin + CJC-1295 no DAC 3+3 mg
Ipamorelin + CJC-1295 no DAC 3+3 mg

Ipamorelin + CJC-1295 no DAC 3+3 mg

Ipamorelin + CJC-1295 3+3 mg — two-component RUO reagent: Ipamorelin (selective GHRP, ghrelin mimetic) plus CJC-1295 (GHRH analogue, variant with/without DAC according to COA) in the lyophilisate for reconstitution. Two complementary arms of the GH axis in one research tool: GHRH increases the pulse amplitude, GHRP increases the frequency and suppresses somatostatin – synergistic, pulsatile release of growth hormone.

33,99 €
With code BLACK: 27,19 € Lowest price in the 30 days before the discount: 33,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

Ipamorelin + CJC-1295 3+3 mg - two-component blend GH-secretagogue (GHRP + GHRH)

  • Ipamorelin + CJC-1295: two complementary growth hormone secretagogues.
  • Lyophilisate in a vial: nominally 3 mg + 3 mg, or 6 mg total; CJC-1295 variant according to the COA.
  • Research Use Only reagent, not a medicinal product.

Adjustment frame – two-component blend of GH secretagogues

Ipamorelin + CJC-1295 3+3 mg is two-component research reagent in the form of a lyophilisate in a vial, containing Ipamorelin (growth hormone releasing peptide, GHRP – ghrelin mimetic) and CJC-1295 (an analogue of growth hormone releasing hormone, GHRH). Each of these assets has its own regulatory status – and none of them make this reagent a drug.

Both peptides are not registered as medicinal products in any jurisdiction. Both molecules belong to the class of growth hormone secretagogues, which WADA lists in section S2 of the prohibited list (peptide hormones, growth factors and mimetics) – permanently prohibited substances, both in and outside competitions. Communication suggesting human use to increase growth hormone, IGF-1 levels, accelerate recovery or body composition is contrary to the Research Use Only framework and is unacceptable.

Introduction

The secretion of growth hormone is not a flat, steady stream – the pituitary gland releases GH impulses, in pulses of a specific amplitude and frequency, regulated by a pair of opposing signals from the hypothalamus. On the one hand, GHRH (growth hormone releasing hormone) tells the pituitary to “release”, on the other hand, somatostatin says “hold”.

Superimposed on this system is a third player – ghrelin and its receptor (GHS-R1a) – which acts as a separate, complementary switch for GH release. The pharmacology of growth hormone secretagogues arises precisely from the question: what happens when we stimulate these pathways separately, and what happens when we stimulate them together? Blend Ipamorelin + CJC-1295 is a classic research pair answering the second part of this question.

Ipamorelin stimulates the ghrelin receptor (GHS-R1a) – mimics the ghrelin arm, acting as GHRP. CJC-1295 stimulates the GHRH receptor – strengthens the GHRH arm. Each of them triggers GH release by a different mechanism; combined, they act on two complementary inputs of the same somatotropic pituitary cell. This is the rationale for which research protocols on the physiology of the GH/IGF-1 axis combine a GHRH analogue with a GHRP class peptide – a topic that this reagent isolates as a laboratory tool.

The guide discusses the broader context of the use of this class of molecules in bodybuilding sports peptides in bodybuilding. This reagent is supplied as lyophilisate 3+3 mg, or 6 mg in total in a vial (proportion of Ipamorelin to CJC-1295 given in the batch COA), for reconstitution with bacteriostatic water in laboratory conditions. The freeze-dried form ensures the stability of both peptides before dissolution and allows researchers to prepare working concentrations tailored to the experimental design.

Purity of each ingredient verified by HPLC ≥98%, identity of both peptides confirmed by Q-TOF mass spectrometry, COA available for each batch. Single-component lines remain available in parallel: Ipamorelin as a ghrelin mimetic itself and CJC-1295 with DAC as a GHRH analogue alone – reference points for comparative studies in each arm separately.

General description - GHRH/GHRP axis and pulsatile GH secretion

To understand why you need to combine two peptides acting on growth hormone, you need to see that the pituitary gland receives the “secret GH” signal through more than one channel. The somatotropic cell of the anterior pituitary has at least two separate receptors on its surface that stimulate the release of growth hormone: GHRH receptor and growth hormone secretion receptor type 1a (GHS-R1a), i.e. ghrelin receptor.

These are two different proteins, two different intracellular cascades and two different physiological signals – which converge on the same end result, the release of GH from secretory granules. GHRH receptor is a receptor coupled to the Gs protein. Its stimulation increases intracellular cAMP, activates the PKA kinase-dependent pathway and leads to the release of growth hormone.

Physiologically, GHRH is primarily responsible for amplitude GH pulse – for how high a single hormone release is. This is the channel on which CJC-1295 is based. Ghrelin receptor (GHS-R1a) is a Gq protein-coupled receptor. Its stimulation activates phospholipase C, increases intracellular calcium and also leads to the release of GH – but in a way separate from GHRH.

Importantly, the ghrelin arm additionally suppresses somatostatin (inhibiting hormone) and enhances its own GHRH action. Physiologically, secretagogues acting on this receptor influence frequency and pulsatility GH release. This is the channel on which Ipamorelin is based. The pulsatile nature of GH secretion is the main physiological detail here – and that is why the GHRH + GHRP pair is an interesting research model.

Unlike exogenous, recombinant growth hormone, which floods the circulation with a flat, nonphysiological concentration, secretagogues stimulate own pituitary to release GH in a way that preserves the pulsatile signal architecture – involving the somatostatin feedback loop. This “endogenous, pulsatile” release pattern is the subject of research on the physiology of the GH/IGF-1 axis, the regulation of slow-wave sleep (in which the strongest nocturnal GH pulse occurs), and the differences between secretagogue stimulation and the administration of recombinant GH. The pharmacology of growth hormone secretagogues includes two large classes of tools:

  • GHRH analogues — mimic the endogenous GH-releasing hormone, stimulate the GHRH receptor, increase the pulse amplitude (CJC-1295, sermorelin, tesamorelin)
  • GH-releasing peptides (GHRP) and ghrelin mimetics — stimulate the GHS-R1a ghrelin receptor, increase the pulse rate and suppress somatostatin (Ipamorelin, GHRP-2, GHRP-6, hexarelin)

Blend Ipamorelin + CJC-1295 combines one representative of each class – one GHRH analogue and one ghrelin mimetic – making it a model tool for testing interaction of both arms regulation of growth hormone release in one, controlled experimental system. The full range of molecules from this family is collected in the category growth hormone-increasing peptides.

What is the Ipamorelin + CJC-1295 blend - two active ingredients

Blend it a combination of two distinct peptides in one lyophilisate, in the proportion given in the COA of the batch. Below is the description of each of them separately.

Ingredient 1 – Ipamorelin (GHRP, ghrelin mimetic)

Ipamorelin is selective pentapeptide from the class of growth hormone releasing peptides (GHRP) — synthetic ghrelin mimetic, growth hormone secretion receptor type 1a (GHS-R1a) agonist. Stimulation of this receptor on somatotropic pituitary cells leads to pulsatile GH release and suppression of somatostatin. The distinguishing feature of Ipamorelin in the reference literature is its selectivity: unlike older GHRPs (esp GHRP-6, to a lesser extent GHRP-2), in preclinical models it did not significantly increase the level of cortisol or prolactin, and the effect on ACTH release was limited (Raun et al. 1998).

This “pure” GH secretagogue profile – GH stimulation without the simultaneous release of stress hormones – has made Ipamorelin one of the most frequently cited selective growth hormone secretagogues in the literature.

Parameter Value
Common name Ipamorelin
Pharmacological class Growth Hormone Releasing Peptide (GHRP); selective ghrelin receptor agonist (GHS-R1a)
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (pentapeptide, C-terminal amide)
CAS number 170851-70-4
Molecular formula C₃₈H₄₉N₉O₅
Molar mass ~711.85 g/mol
Mechanism GHS-R1a agonist → pulsatile GH release; somatostatin suppression; selective (no significant increase in cortisol/prolactin in preclinical models)
Nominal content per vial Nominally 3 mg; 6 mg total per vial (content confirmed in the batch COA)
HPLC purity ≥98%
Identity confirmation Q-TOF mass spectrometry

Ingredient 2 – CJC-1295 (GHRH analogue)

CJC-1295 is a modified growth hormone releasing hormone analogue — a derivative of the GHRH(1-29) fragment, i.e. a shorter, biologically active section of human GHRH. Class: GHRH receptor agonist on pituitary somatotropic cells; stimulation of this receptor increases the amplitude of the growth hormone pulse. CJC-1295 is currently in the research market two structural variants, which must not be confused:

  • CJC-1295 without DAC (also known as Mod-GRF 1-29 or modified GRF 1-29) – the modified GHRH(1-29) fragment itself with substitutions that stabilize the peptide against enzymatic degradation; shorter half-life.
  • CJC-1295 with DAC (from Drug Affinity Complex) – the same GHRH(1-29) core with an albumin affinity complex (maleimide linker that binds to serum albumin) attached. The addition of DAC significantly extends the half-life because albumin serves as a reservoir for the molecule in the circulation. In the clinical program (Teichman et al. 2006) conducted by ConjuChem, prolonged binding to albumin resulted in sustained, multi-day stimulation of GH and IGF-1 secretion.

The variant included in the blend (with or without DAC) is given in the batch COA — this is a specification that the researcher must verify before planning the experiment, because the pharmacokinetic profile of both variants is fundamentally different.

Parameter Value
Common name CJC-1295 (with or without DAC – by batch COA)
Pharmacological class GHRH analogue; GHRH receptor agonist
Origin of the molecule Modified fragment of GHRH(1-29); the DAC variant contains an albumin affinity complex
CAS number 863288-34-0 (variant with DAC) (to be verified in the batch COA)
Structural modifications GHRH(1-29) stabilizing substitutions; in the DAC variant – albumin-binding linker (long-term action)
Mechanism GHRH receptor agonist → increase in GH pulse amplitude
Performance profile Non-DAC variant: shorter half-life; variant with DAC: extended (albumin reservoir)
Nominal content per vial Nominally 3 mg; 6 mg total per vial (content confirmed in the batch COA)
HPLC purity ≥98%
Identity confirmation Q-TOF mass spectrometry

SCIENTIFIC PERSPECTIVE

Data on Ipamorelin come mainly from preclinical models (pig, rat, isolated pituitary cells) and early pharmacological characterization (Raun et al. 1998). Data for CJC-1295 with DAC come from early ConjuChem Phase I clinical trials (Teichman et al. 2006) and GH pulsatility analyses. Synergistic stimulation of GH secretion by the GHRH + GHRP pair has been described in the literature on the physiology of the somatotropic axis.

The Ipamorelin + CJC-1295 3+3 mg (RUO) reagent was not the subject of these studies as a therapeutic form – the mechanisms and endpoints described are of a reference nature, they describe the profile of molecules in the literature, and not the expected result of work with the RUO reagent. Extrapolation of PK/PD profiles to any human application requires caution and is inconsistent with the Research Use Only framework.

Two-component mechanism - GHRH amplitude plus GHRP frequency

The operation of the blend is based on simultaneous stimulation of two separate growth hormone-releasing receptors on the same somatotropic pituitary cell. This is what distinguishes Ipamorelin + CJC-1295 from a single secretagogue: it is not about one stronger stimulus, but about two complementary inputs that the physiology of the GH axis treats differently.

GHRH Axis (CJC-1295) – Amplitude. Activation of the GHRH receptor (coupled to Gs protein) increases intracellular cAMP and triggers the PKA kinase-dependent pathway. The effect is increasing pulse amplitude — a single release of growth hormone becomes higher. In a working analogy: The CJC-1295 regulates the “volume” of the GH signal. In the DAC variant, prolonged binding to albumin maintains this amplitude stimulation for hours to days, sustaining elevated GH release and—secondarily—hepatic IGF-1 production.

Ghrelin axis (Ipamorelin) – frequency and pulsatility. Activation of the GHS-R1a ghrelin receptor (coupled to Gq protein) triggers the phospholipase C pathway and increases intracellular calcium – through a different cascade than GHRH. Additionally, the ghrelin arm suppresses somatostatin, i.e. it removes the brake from the somatotropic cell. The effect is to influence frequency and pulsatility GH release and enhancement of the response to GHRH. In an analogy: Ipamorelin regulates the “rhythm” of ejection and takes your foot off the brake.

Synergy, not a simple sum. This is the essence of combining GHRH + GHRP. Because both peptides work through different receptors and different intracellular cascades, and the ghrelin arm additionally abolishes somatostatin inhibition, simultaneous stimulation of both pathways produces an effect in the models greater than the sum of each individual’s actions — this is a synergy phenomenon described in the physiology of the somatotropic axis for pairs of a GHRH analogue and a ghrelin secretagogue.

Mechanistically: GHRP increases the amplitude of the GHRH response (by suppressing somatostatin and direct stimulation of GHS-R1a), and GHRH provides a strong Gs/cAMP signal – two arms that mutually reinforce each other at the single-cell level. The effect is stronger, physiologically pulsatile release of growth hormone — a signal that mimics the endogenous secretion pattern better than exogenous recombinant GH.

Applications in scientific research

Blend Ipamorelin + CJC-1295 as a two-component RUO reagent is used where the subject of the study is interaction of the GHRH axis with the ghrelin axis in regulating the release of growth hormone. A constant proportion of both peptides in one lyophilisate simplifies protocols in which both molecules are to be administered to the model together.

In vivo models (rat, mouse, pig as a model species for GH physiology) and in vitro models (isolated somatotropic pituitary cells, cell lines expressing the GHRH receptor or GHS-R1a) are used to investigate the mechanism, kinetics and synergy of GH release. Specific research directions include:

  • Pharmacology of GHRH + GHRP synergy — measurements of GH release from isolated pituitary cells when stimulated separately by GHRH, separately by GHRP and both simultaneously; quantitative characterization of the additive vs. synergistic effect, concentration-response curves for both receptors in parallel
  • Pulsatility and architecture of GH secretion — studies of how the secretagogue pair modifies the amplitude and frequency of GH pulses in animal models; comparison of the release pattern with stimulation with a single peptide and with the administration of recombinant GH
  • Somatostatin axis — the role of somatostatin suppression by the ghrelin arm in the potentiation of the GHRH response; studies of the feedback loop regulating the GH pulse
  • Receptor selectivity of Ipamorelin — comparative studies on the selectivity of GHRP towards the ghrelin receptor and limited effect on the cortisol/prolactin/ACTH axis (Ipamorelin vs GHRP-6 vs GHRP-2) in cell preparations
  • Effect of the DAC variant on pharmacokinetics — comparison of the time profile of GH stimulation for CJC-1295 with DAC (prolonged albumin retention) and without DAC (shorter exposure) in in vivo models; research on the structure-action time relationship
  • GH/IGF-1 axis and secondary markers — IGF-1 measurements as a secondary marker of sustained GH stimulation in animal models; studies on hepatic IGF-1 production in response to a pulsed vs. continuous GH signal

REGULATORY STATUS

Both Ipamorelin and CJC-1295 belong to the class growth hormone secretagogues, which WADA lists in section S2 of the prohibited list — “peptide hormones, growth factors, related substances and mimetics”. This section includes growth hormone releasing factors (GHRH and its analogues, including CJC-1295, sermorelin, tesamorelin) and GH-releasing peptides and ghrelin mimetics (GHRP, including Ipamorelin, GHRP-2, GHRP-6).

These substances are prohibited permanently — both in and out of competition. There is an absolute ban for registered athletes (ADAMS). Neither Ipamorelin nor CJC-1295 is registered as a medicinal product in the EU, USA or anywhere in the world (the clinical program of CJC-1295 with DAC conducted by ConjuChem did not lead to registration). Registered athletes must check the current list of prohibited substances before making any decision regarding use.

Summary

Ipamorelin + CJC-1295 3+3 mg is two-component RUO research reagent — lyophilisate in a vial combining two complementary growth hormone secretagogues: Ipamorelin (selective GHRP pentapeptide, ghrelin mimetic, GHS-R1a agonist) and CJC-1295 (GHRH analogue, variant with or without DAC according to COA of the batch). The rationale of the blend lies in the pharmacology of the somatotropic axis: GHRH (CJC-1295) increases amplitude GH pulse through the Gs/cAMP-coupled receptor, and GHRP (Ipamorelin) increases frequency and pulsatility through the Gq ghrelin receptor and suppresses somatostatin.

By acting on two separate receptors on the same somatotropic cell, the pair produces an effect in the models synergistic — stronger, physiologically pulsatile GH release, greater than each peptide alone. Lyophilized form: 6 mg total in a vial, reconstitution with bacteriostatic water, HPLC purity ≥98% for both components, MS Q-TOF, COA for each batch with confirmation of proportion and CJC-1295 variant. Regulatory Status – Research Use Only; lack of registration as a medicine; WADA: section S2, permanently prohibited substances.

Bibliography

  1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue. PubMed
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. PubMed
  3. Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. PubMed
  4. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogue. PubMed
  5. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. PubMed